| Literature DB >> 29245939 |
Xiaolu Huang1, Yiwen Zhou1, Wenhui Liu1, Haizhou Li1, Xiao Liang1, Rui Jin1, Hengyu Du1, Jizhou He1, Bangda Chai1, Ran Duan1, Qingfeng Li1.
Abstract
Silicone implants are used widely in the field of plastic surgery and are used in a large population. However, their safety profile, especially the silicone-induced immune response, has been a major concern for plastic surgeons for decades. It has been hypothesized that there is a cause and effect relation between silicone and immunity, but this is controversial. The objective of the present study was to determine the hub genes and key pathways related to silicone implant-induced immune responses in a rat model. In addition to cluster and enrichment analyses, we used weighted gene co-expression network analysis (WGCNA) to examine the gene expression profiles in a systematic context. A total five genes (Fes, Aif1, Gata3, Tlr6, Tlr2) were identified as hub genes that are most likely related to the silicone-induced immune response, four of which (Aif1, Gata3, Tlr6, Tlr2) have been associated with autoimmunity as target genes or disease markers. The Toll-like receptor signaling pathway (p < 0.01, fold enrichment: 7.01) and systemic lupus erythematosus signaling pathway (p < 0.05, fold enrichment: 5.01), which are considered strongly associated with autoimmunity, were significantly enriched in the silicone-implanted skin samples. The results indicate that silicone implants might trigger the localized immune response, as various immune reaction genes were detected after silicone implantation. The identified five hub genes will hopefully serve as novel therapeutic targets for silicone-related complications and the associated autoimmune diseases.Entities:
Keywords: WGCNA; autoimmunity; hub genes; microarray; silicone implant
Year: 2017 PMID: 29245939 PMCID: PMC5725130 DOI: 10.18632/oncotarget.21546
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow chart of bioinformatics analyses of hub genes and pathways related to immune response after silicone implantation
Figure 2STEM cluster analysis of 80 significantly differential genes after silicone implantation
Two trends (p < 0.001) with a statistically significant number of genes were assigned. The boxes on the left side of the figure contain detailed information on these two profiles. In the boxes, the number in the top left corner represents the profile ID, the bottom right corner shows the p-value, and the bottom left corner shows the gene number assigned to the profile. Details of the genes mapped to each temporal profile are in Supplementary Table 2.
The summary of GO terms in significant expression patterns profiles
| Category ID | Category Name | Genes Category | Genes Assigned | Genes Expected | Genes Enriched | Corrected | Fold | |
|---|---|---|---|---|---|---|---|---|
| immune response | 396 | 49 | 17.8 | 31.2 | 2.50E-11 | < 0.001 | 2.7 | |
| leukocyte activation | 286 | 35 | 12.9 | 22.1 | 3.60E-08 | < 0.001 | 2.7 | |
| response to bacterium | 275 | 34 | 12.4 | 21.6 | 4.40E-08 | < 0.001 | 2.7 | |
| response to wounding | 476 | 48 | 21.4 | 26.6 | 4.50E-08 | < 0.001 | 2.2 | |
| immune effector process | 226 | 30 | 10.2 | 19.8 | 6.00E-08 | < 0.001 | 2.9 | |
| regulation of immune system process | 401 | 42 | 18.1 | 23.9 | 1.30E-07 | 0.002 | 2.3 | |
| regulation of cell activation | 212 | 28 | 9.5 | 18.5 | 1.90E-07 | 0.002 | 2.9 | |
| response to molecule of bacterial origin | 230 | 29 | 10.4 | 18.6 | 3.10E-07 | 0.002 | 2.8 | |
| regulation of response to external stimulus | 248 | 30 | 11.2 | 18.8 | 4.80E-07 | 0.002 | 2.7 | |
| lymphocyte activation | 238 | 29 | 10.7 | 18.3 | 6.50E-07 | 0.004 | 2.7 | |
| response to lipopolysaccharide | 221 | 27 | 10 | 17 | 1.60E-06 | 0.004 | 2.7 | |
| inflammatory response | 271 | 30 | 12.2 | 17.8 | 3.20E-06 | 0.004 | 2.5 | |
| leukocyte activation involved in immune response | 76 | 14 | 3.4 | 10.6 | 5.50E-06 | 0.01 | 4.1 | |
| cell activation involved in immune response | 76 | 14 | 3.4 | 10.6 | 5.50E-06 | 0.01 | 4.1 | |
| regulation of leukocyte activation | 189 | 23 | 8.5 | 14.5 | 1.00E-05 | 0.022 | 2.7 | |
| regulation of lymphocyte activation | 163 | 21 | 7.3 | 13.7 | 1.10E-05 | 0.022 | 2.9 | |
| myeloid leukocyte activation | 75 | 13 | 3.4 | 9.6 | 2.40E-05 | 0.034 | 3.8 | |
| immune response | 396 | 31 | 9.8 | 21.2 | 4.70E-09 | < 0.001 | 3.2 | |
| regulation of immune system process | 401 | 28 | 10 | 18 | 3.50E-07 | < 0.001 | 2.8 | |
| inflammatory response | 271 | 22 | 6.7 | 15.3 | 6.30E-07 | < 0.001 | 3.3 | |
| positive regulation of immune system process | 261 | 21 | 6.5 | 14.5 | 1.40E-06 | < 0.001 | 3.2 | |
| immune effector process | 226 | 18 | 5.6 | 12.4 | 9.60E-06 | 0.01 | 3.2 | |
| myeloid leukocyte activation | 75 | 10 | 1.9 | 8.1 | 1.30E-05 | 0.016 | 5.4 | |
| positive regulation of leukocyte activation | 128 | 13 | 3.2 | 9.8 | 1.40E-05 | 0.018 | 4.1 | |
| positive regulation of acute inflammatory response | 23 | 6 | 0.6 | 5.4 | 1.50E-05 | 0.024 | 10.5 | |
| hemopoiesis | 260 | 19 | 6.5 | 12.5 | 1.80E-05 | 0.028 | 2.9 | |
| negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 15 | 5 | 0.4 | 4.6 | 2.20E-05 | 0.04 | 13.4 | |
| negative regulation of adaptive immune response | 16 | 5 | 0.4 | 4.6 | 3.10E-05 | 0.046 | 12.6 | |
| regulation of immune effector process | 119 | 12 | 3 | 9 | 3.30E-05 | 0.05 | 4.1 | |
Summary of statistically significant key pathways
| Term | Genes | Count | % | Fold Enrichment | FDR | |
|---|---|---|---|---|---|---|
| Cytokine-cytokine receptor interaction | CSF3, CCL3, TNF, CCL2, CSF1, CXCL2, CXCL9, TNFSF13, PF4, IL7R, TNFSF18, CCL4, IL10, CXCL10, OSM, CSF1R | 16 | 1.714898 | 1.60E-09 | 7.322744 | 1.73E-06 |
| Hematopoietic cell lineage | CSF3, CD38, CD55, CD37, TNF, CSF1, FCGR1A, IL7R, CD14, CSF1R | 10 | 1.071811 | 1.21E-07 | 11.55914 | 1.31E-04 |
| Chemokine signaling pathway | CXCL1, CCL3, CCL2, CXCL2, CXCL9, CCL9, JAK2, PF4, CCL4, CCL7, CCL6, CXCL10 | 12 | 1.286174 | 1.76E-06 | 6.327108 | 0.001906 |
| Toll-like receptor signaling pathway | CCL3, TNF, TLR2, CXCL9, TLR6, CD14, CXCL10 | 7 | 0.750268 | 4.02E-04 | 7.012545 | 0.433237 |
| NOD-like receptor signaling pathway | CXCL1, TNF, CCL2, CXCL2, CCL7 | 5 | 0.535906 | 0.004465 | 7.271072 | 4.721757 |
| Systemic lupus erythematosus | TNF, FCGR2B, C6, FCGR1A, IL10 | 5 | 0.535906 | 0.01632 | 5.008961 | 16.29149 |
| Jak-STAT signaling pathway | OSM, CSF3, STAT5A, JAK2, IL7R, IL10 | 6 | 0.643087 | 0.017261 | 3.891854 | 17.15306 |
| Natural killer cell mediated cytotoxicity | ITGAL, TNF, FCGR2B, FCER1G, TYROBP | 5 | 0.535906 | 0.023113 | 4.508065 | 22.33229 |
| Asthma | TNF, FCER1G, IL10 | 3 | 0.321543 | 0.025582 | 11.76017 | 24.4271 |
| Fc gamma R-mediated phagocytosis | PTPRC, GAB2, FCGR2B, FCGR1A | 4 | 0.428725 | 0.070663 | 4.09824 | 54.70701 |
| Cell adhesion molecules (CAMs) | ALCAM, ITGAL, PTPRC, CD274, SPN | 5 | 0.535906 | 0.077219 | 3.04599 | 58.04327 |
| Intestinal immune network for IgA production | TNFSF13, IL10, TGFB1 | 3 | 0.321543 | 0.086023 | 6.010753 | 62.17279 |
| Cytosolic DNA-sensing pathway | IL33, CCL4, CXCL10 | 3 | 0.321543 | 0.089322 | 5.880084 | 63.62241 |
Figure 3Identification of two autoimmunity-related signaling pathways
Top: SLE signaling pathway; bottom: TLR signaling pathway. Red stars indicate the significantly expressed genes in the pathways.
Figure 4Gene co-expression network
Genes contained in significant GO terms were analyzed and identified by the gene co-expression network using the k-core algorithm. Nodes represent genes; edges indicate the interaction between the genes. The area of each node represents the k-core value within the module, and the edge correlates with the capacity for modulating adjacent genes. Genes with higher k-core values are more centralized in the network and have a stronger capacity for modulating adjacent genes.
Figure 5Heat map of distribution of top 25 genes in 25 significant GO terms
The bar on the right indicates if the gene is a participat in the GO term (light blue, yes; dark blue, no).